Inhibitors
- VHL ligand 2 hydrochloride [orb611997]
>98%
[1948273-03-7]
413.4
C21H18F3N5O
O=C (C1CC1)NC2=CC=CC (NC3=NC=CC (NC4=CC=CC (C (F) (F)F)=C4)=N3)=C2
1 g, 2 g, 5 g - Aurora Kinase Inhibitor III [orb611996]
>98%
[879127-16-9]
413.4
C21H18F3N5O
O=C (C1CC1)NC2=CC=CC (NC3=NC=CC (NC4=CC=CC (C (F) (F)F)=C4)=N3)=C2
100 mg, 250 mg, 1 g - ZT-12-037-01 [orb611995]
>98%
[2328073-61-4]
385.512
C21H31N5O2
COC1=CC2=NC (NC3CC3)=NC (NC4CCN (C (C)C)CC4)=C2C=C1OC
100 mg, 250 mg, 1 g - YW1159 [orb611994]
>98%
[2131223-69-1]
347.3
C19H14FN5O
O=C (C1=C (C)N (C2=C (F)C=CC=C2)N=N1)NC3=CC=C (C=CC=C4)C4=N3
100 mg, 250 mg, 1 g - STING Agonist C11 [orb611993]
>98%
[875863-22-2]
382.4
C19H18N4O3S
O=C (NC (NC)=O)C (SC1=NN=C (C2=CC=C (C)C=C2)O1)C3=CC=CC=C3
100 mg, 250 mg, 1 g - SR 16832 [orb611992]
>98%
[2088135-12-8]
357.7
C17H12ClN3O4
COC1=CC=C2C (C (NC (C3=CC ([N+] ([O-])=O)=CC=C3Cl)=O)=CC=N2)=C1
100 mg, 250 mg, 1 g - Questiomycin A [orb611991]
>98%
[1916-59-2]
212.2
C12H8N2O2
NC1=CC2=NC3=CC=CC=C3OC2=CC1=O
100 mg, 250 mg, 1 g - H-Gly-Arg-pNA (hydrochloride) [orb611990]
>98%
[125455-61-0]
424.3
C14H21N7O4.2HCl
O=C ([C@@H] (NC (CN)=O)CCCNC (N)=N)NC1=CC=C ([N+] ([O-])=O)C=C1.Cl.Cl
100 mg, 250 mg, 1 g - Diprotin A [orb611989]
>98%
[90614-48-5]
341.5
C17H31N3O4
O=C ([C@@H] (N)[C@@H] (C)CC)N1CCC[C@H]1C (N[C@H] (C (O)=O)[C@@H] (C)CC)=O
100 mg, 250 mg, 1 g - Cathepsin L inhibitor III [orb611988]
>98%
[114014-15-2]
542.6
C31H34N4O5
O=C (N[C@@H] (CC1=CC=CC=C1)C (N[C@H] (C (C=[N+]=[N-])=O)CC2=CC=C (OC (C) (C)C)C=C2)=O)OCC3=CC=CC=C3
100 mg, 250 mg, 1 g
